Table of Contents
Introduction Sitagliptin
Sitagliptin, marketed under the brand name Januvia, is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to treat type 2 diabetes. It enhances the body’s natural ability to regulate blood sugar by increasing the levels of incretin hormones.
Mechanism of Action Sitagliptin
Sitagliptin works by inhibiting the enzyme DPP-4, which breaks down incretin hormones. These hormones increase insulin release from pancreatic beta cells and decrease glucagon secretion from alpha cells, resulting in lower blood glucose levels.
Clinical Applications Sitagliptin (Januvia)
Januvia is often prescribed in combination with other antidiabetic medications, such as metformin, to improve glycemic control. It is well-tolerated and associated with a low risk of hypoglycemia, making it a suitable option for many patients.
Side Effects Sitagliptin (Januvia)
Common side effects of Sitagliptin include upper respiratory tract infections, headaches, and nasopharyngitis. It has a favorable safety profile, but rare cases of pancreatitis have been reported, necessitating careful monitoring.
Conclusion
Sitagliptin is a valuable addition to the diabetes treatment landscape, offering an effective and well-tolerated option for improving glycemic control. Its mechanism of action and low risk of hypoglycemia make it a preferred choice for many patients.